Key Takeaways
- Revenue up, EBITDA down sharply: Revenue grew 2% YoY to ₹85.9 crore, but EBITDA fell 36% YoY to ₹7.1 crore (8.2% margin) as operational expenses spread across still-small volumes crushed profitability.
- Electrolyte Salts surged, but lumpy: The segment jumped 101% QoQ to ₹2.5 crore, yet management flagged this as a one-time catch-up that will smoothen into consistent demand from April 2025.
- Pricing has bottomed, raw materials ticking up: Management declared pricing "almost stabilized" with no further downward revisions, while certain key raw materials are seeing an uptick, a potential margin headwind if volumes do not rise fast enough.
- A pipeline of approvals is converting to revenue now: Two new MNC PTC customers onboarded, four PASC agro intermediates commercializing, photochlorination shipments from April, and the first polymer shipment due mid-February.
- What to watch next quarter: Whether the ₹80–100 crore PASC revenue guidance for next year starts to materialize from May 2025 volumes, and whether the distillation plant’s 12–15% capacity unlock translates into margin recovery.
The Margin Squeeze: Volume Is the Only Cure
- Operational expenses are the culprit: The core problem is fixed operational costs spread across low volumes, management stated that as volumes increase, a "significant and positive impact on profit margins" will follow.
- Goods in transit masked no benefit: ₹11 crore of goods remained in transit this quarter due to 8–9 week shipping times to the U.S. and 7–8 weeks to Europe, so the EBITDA boost expected from last quarter’s transit goods never landed.
- Gross margin dilution is structural: New agro products carry higher gross margins individually but require larger capex (capex-to-revenue of 1–1.2x vs PTC’s ~3x), so the blended gross margin will settle around 45%, down from 52% historically.
- Distillation plant now operational: Started in January 2025, it frees up at least 12–15% of plant space and will be used for product distillation for new agro products including photochlorination.
- Process excellence team deployed: A new internal team is identifying bottlenecks for minor investments to boost productivity and optimize reaction times, an acknowledgment that operational efficiency needs work.
Chintan Shah: "The current issue lies with the overall operational expenses, which are spread across smaller volumes. However, as soon as there is an increase in volume, we can expect to see a significant and positive impact on our profit margins."
PASC: The Near-Term Growth Engine
- Four agro intermediates commercializing now: Two products already have POs and production underway, the two largest products will see regular shipments from April/May 2025, and final clearance for two more is expected within the current quarter.
- Photochlorination contract imminent: Approvals are in place, a customer visit is scheduled for end-February for contract discussions, and shipments are to begin from April 2025.
- Pharma intermediates on a slower clock: Three products formally approved with gradual commercialisation from end of 2025 or early 2026, a fourth still in the approval process with commercialisation by end of next calendar year.
- Revenue guidance offered: Management expects PASC revenue of at least ₹80–100 crores next year, with EBITDA margins becoming "much healthier" once volumes hit from May 2025.
- New plant to relieve capacity: The Dahej plant for new agro products is expected ready for production in Q4 FY2026, while the existing plant should be almost fully occupied by June or July 2025.
PTCs: New Customers, New Application, Slow Ramp
- Two MNC customers onboarded: Commercial business has begun for existing PTC products but in a new application, a specialty polymer/recyclable plastic, with dispatches already underway this quarter.
- Segment grew 19% YoY: PTC revenue reached ₹29.5 crore, up 7% QoQ, driven by the new customer wins.
- Ramp will take 6–8 months: Management cautioned that stabilizing business with new customers requires time for logistics, contracts, and multi-location suitability, after which a "quite significant jump" in PTC business is expected.
Chintan Shah: "This is basically getting into some kind of specialty polymer. And theoretically speaking, if I can just largely say it is kind of a recyclable plastic application where they are using."
SDAs: Cyclical Bottom, Green Shoots Visible
- Demand remained subdued: The Chinese market for heavy-duty commercial vehicles stayed weak, keeping SDA volumes low.
- Two large customers ready to begin: Approved in 2024, they are now discussing logistics and warehousing for multiple global locations, with commercial supplies starting from April 2025.
- Customers signaling an uptick: Two large SDA customers have indicated to prepare for higher demand, with end-use customers seeing improvement in IC engines and hybrid engines, and China slowly starting to ramp up.
- EURO 7 norms a tailwind: Implementation remains on track, with improving demand expected within a couple of quarters.
- New non-auto applications emerging: A desulfurization-of-fuel application is commercializing, and a plastic recycling catalyst was approved in 2024 though still in R&D/piloting, reducing long-term cyclicality risk.
- U.S. EV policy shift helps SDAs: Management argued that discouraging EVs will have a positive impact on SDA business as it boosts hybrid and IC engine demand.
Chintan Shah: "They are discouraging the use of EV, and this will have a positive impact on the business of SDAs."
Electrolyte Salts & Energy Storage: A Unique Position Taking Shape
- Revenue surged 101% QoQ: Electrolyte Salts hit ₹2.5 crore, but management called out the lumpiness and said sales will smoothen into consistent demand from April as the customer’s production lines have stabilized.
- Electrolyte formulation advancing: Lab-scale results were encouraging, the customer has requested scale-up to pilot scale expected to run by April, and success would put the company in a unique position of making both salts and formulating the electrolyte.
- Hybrid vehicle qualification progressing: The qualification process with a key battery manufacturer for hybrid cars is going well.
- Supercapacitor chemicals tied to hybrids: Management noted that Europe’s shift to hybrid vehicles will push supercapacitor demand "drastically high."
Chintan Shah: "This is a very exciting development for us which can lead us to a very unique position wherein we make the salts ourselves and are also able to formulate the electrolyte ourself. This will give us a unique competitive advantage and a potential to significantly increase our presence in the segment of energy storage."
Semiconductor & High-Purity: The Three-Year Bet
- High-purity water plant operational: A plant producing very large volumes of water below 1 PPB level for semiconductor-grade chemical production is now commercially set up, overcoming a three-year obstacle.
- Analytics capability established: The company can now test below 1 PPB (parts per trillion levels), a prerequisite for semiconductor material qualification.
- TMAH below 1 PPB within 4–6 months: Management has identified 3–4 contamination points being rectified and expects to crack the ultra-high-purity threshold soon, which would make Tatva Chintan the first Indian company to qualify for these grades.
- Semiconductor will take three years to become a growth engine: Management flagged the segment as a focus area but cautioned that significant headway in ultra-high-purity quality requirements will take time.
Chintan Shah: "If this works through, probably we will be the first company in India to have qualified for these grades of high-purity semiconductor material."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| PASC revenue | At least ₹80–100 crores revenue | Next year (FY26) |
| PASC margin recovery | EBITDA margins become "much healthier" | Once volumes hit from May 2025 |
| Existing plant full utilization | Almost fully occupied | June or July 2025 |
| New plant operational | Dahej plant ready for production | Q4 FY2026 / January 2026 |
| SDA commercial supplies | Two large customers begin supplies | April 2025 |
| Electrolyte formulation pilot | Pilot scale run | April 2025 |
| Photochlorination shipments | First shipments begin | April 2025 |
| PASC largest products | Regular shipments rolling out | April or May 2025 |
| Monoglyme commercialisation | Installation and commercialisation | June 2025 |
| Polymer first shipment | First shipment dispatched | Mid-February 2025 |
| Semiconductor-grade TMAH | Crack below 1 PPB threshold | Within 4–6 months |
| Pharma intermediates (3 products) | Gradual commercialisation begins | End of 2025 or early 2026 |
| Pharma intermediate (4th product) | Commercialisation | End of next calendar year |
| PTC new customer ramp | Business stabilizes, then "quite significant jump" | 6–8 months from now |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue from operations | ₹85.9 cr, 2% YoY growth and 3% QoQ growth |
| EBITDA | ₹7.1 cr, 36% decline YoY but 26% increase QoQ |
| EBITDA margin | 8.2%, vs 13.1% in Q3 FY24; COGS up 4.0% YoY and other expenses up 1.1% YoY |
| PAT | ₹0.14 cr, vs ₹3.5 cr in Q3 FY24; PAT margin 0.2% vs 4.1% |
| Exports | ₹52.8 cr, 61% of revenue |
| PTC segment revenue | ₹29.5 cr, 19% YoY growth and 7% QoQ growth |
| Electrolyte Salts segment revenue | ₹2.5 cr, 113% YoY growth and 101% QoQ growth |
| Pharma and Agro Intermediates and Specialty Chemicals revenue | ₹29.8 cr, 18% YoY growth and 10% QoQ growth |
| Raw material consumption | 44–45% of sales, consistent |
| Gross profit margin | 52% currently; guided to stabilize at roughly 45% as product mix shifts |
| Goods in transit | ~₹11 cr, similar to ~₹10–11 cr at end of Q2 FY25; U.S. transit 8–9 weeks, Europe 7–8 weeks |
| Distillation plant capacity freed | At least 12–15% of plant space, operational from January 2025 |
| PASC segment revenue guidance (FY26) | At least ₹80–100 cr |
| Semiconductor-grade TMAH trace metals | 38–60 PPB currently; target below 1 PPB; have recorded 30 PPB |